Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5501 in refractory SLE
NCT06010472Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5501 in systemic lupus erythematosus (SLE), sponsored by Changhai Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 52 weeks and Incidence of Treatment Emergent Adverse Events at 52 weeks. Started Aug 2023; status: recruiting.
02
Drugs
KN5501
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06010472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010472.